MI Bioresearch (MI) is a premier preclinical oncology Contract Research Organization (CRO), offering in vitro and in vivo oncology pharmacology research services to support drug discovery and development programs. Our team explores the effects of clients’ drugs and biologics using an expansive bank of human and syngeneic cancer cell line models and the industry’s widest breadth of and most sophisticated tools with which to interrogate pharmacology. MI Bioresearch provides pharma and biotech companies with decision-driving data to help advance their drug candidate toward the next cancer research breakthrough. One Focus. One Purpose. Oncology Research.
Beringea first invested in MI Bioresearch in 2010.